Barclays PLC Medicinova Inc Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Medicinova Inc stock. As of the latest transaction made, Barclays PLC holds 83,200 shares of MNOV stock, worth $168,895. This represents 0.0% of its overall portfolio holdings.

Number of Shares

83,200

Previous 83,200 -0.0%

Holding current value

$168,895

Previous $121,000 0.83%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.28 - $1.65 $10,368 - $13,365	-8,100 Reduced 8.87%	83,200 $121,000
Q4 2023 Feb 15, 2024	SELL	$1.38 - $2.06 $17,250 - $25,750	-12,500 Reduced 12.04%	91,300 $137,000
Q3 2023 Nov 07, 2023	SELL	$2.01 - $2.6 $17,285 - $22,360	-8,600 Reduced 7.65%	103,800 $217,000
Q2 2023 Aug 03, 2023	SELL	$2.09 - $2.43 $55,802 - $64,881	-26,700 Reduced 19.19%	112,400 $259,000
Q1 2023 May 04, 2023	SELL	$1.95 - $2.54 $18,135 - $23,622	-9,300 Reduced 6.27%	139,100 $300,000
Q4 2022 Feb 13, 2023	SELL	$1.97 - $2.66 $19,503 - $26,334	-9,900 Reduced 6.25%	148,400 $304,000
Q3 2022 Nov 03, 2022	SELL	$2.1 - $2.6 $48,090 - $59,540	-22,900 Reduced 12.64%	158,300 $343,000
Q2 2022 Aug 12, 2022	SELL	$2.31 - $3.14 $7,854 - $10,676	-3,400 Reduced 1.84%	181,200 $458,000
Q1 2022 May 16, 2022	BUY	$2.19 - $2.81 $25,842 - $33,158	11,800 Added 6.83%	184,600 $493,000
Q4 2021 Feb 14, 2022	BUY	$2.61 - $4.42 $49,026 - $83,025	18,784 Added 12.2%	172,800 $463,000
Q3 2021 Nov 09, 2021	BUY	$3.4 - $4.24 $179,710 - $224,109	52,856 Added 52.25%	154,016 $584,000
Q2 2021 Aug 13, 2021	BUY	$3.76 - $5.14 $82,077 - $112,201	21,829 Added 27.52%	101,160 $430,000
Q1 2021 May 13, 2021	BUY	$4.81 - $8.74 $213,895 - $388,659	44,469 Added 127.56%	79,331 $401,000
Q4 2020 Feb 11, 2021	BUY	$5.03 - $6.31 $72,356 - $90,769	14,385 Added 70.25%	34,862 $184,000
Q3 2020 Nov 12, 2020	SELL	$4.67 - $11.0 $12,800 - $30,151	-2,741 Reduced 11.81%	20,477 $108,000
Q2 2020 Aug 12, 2020	BUY	$3.06 - $7.06 $28,604 - $65,996	9,348 Added 67.4%	23,218 $126,000
Q1 2020 May 13, 2020	SELL	$2.9 - $6.97 $81,954 - $196,972	-28,260 Reduced 67.08%	13,870 $52,000
Q4 2019 Feb 10, 2020	BUY	$6.48 - $8.76 $136,935 - $185,116	21,132 Added 100.64%	42,130 $284,000
Q3 2019 Nov 14, 2019	SELL	$7.7 - $10.42 $42,704 - $57,789	-5,546 Reduced 20.89%	20,998 $167,000
Q2 2019 Aug 14, 2019	BUY	$8.29 - $13.22 $119,798 - $191,042	14,451 Added 119.5%	26,544 $256,000
Q1 2019 May 15, 2019	BUY	$6.82 - $10.27 $50,283 - $75,720	7,373 Added 156.21%	12,093 $100,000
Q4 2018 Feb 14, 2019	SELL	$7.65 - $12.83 $78,190 - $131,135	-10,221 Reduced 68.41%	4,720 $39,000
Q3 2018 Nov 14, 2018	BUY	$7.06 - $12.49 $85,249 - $150,816	12,075 Added 421.32%	14,941 $187,000
Q2 2018 Aug 14, 2018	SELL	$7.96 - $13.23 $42,267 - $70,251	-5,310 Reduced 64.95%	2,866 $23,000
Q1 2018 May 15, 2018	BUY	$6.6 - $13.91 $17,259 - $36,374	2,615 Added 47.02%	8,176 $83,000
Q4 2017 Feb 14, 2018	BUY	$5.89 - $7.21 $25,756 - $31,529	4,373 Added 368.1%	5,561 $36,000
Q3 2017 Nov 14, 2017	BUY	$4.43 - $6.58 $5,262 - $7,817	1,188	1,188 $8,000

Others Institutions Holding MNOV

# of Institutions

Shares Held

4.69M

Call Options Held

7.2K

Put Options Held

3.8K

View Full List

About MEDICINOVA INC

Ticker MNOV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,046,200
Market Cap $99.6M
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...

More about MNOV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account